For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
4
views
0
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      3,831
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Covid-19 update: Tocilizumab (Actemra) FDA-approved for treatment of COVID-19.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Med Lett Drugs Ther
          Title: The Medical letter on drugs and therapeutics
          Publisher: The Medical Letter, Inc.
          ISSN (Electronic): 1523-2859
          ISSN (Print): 0025-732X
          Publication date (Electronic): Jan 09 2023
          Volume: 65
          Issue: 1667
          Article
          DOI: 10.58347/tml.2023.1667d
          PubMed ID: 36649082
          SO-VID: 9fd6f8ac-5f08-424a-8f94-fdcb48d4e1e3
          History

          Keywords: COVID-19,tocilizumab,Actemra,Olumiant,baricitinib,dexamethasone,dosage,efficacy
          Data availability:
          Keywords: COVID-19, tocilizumab, Actemra, Olumiant, baricitinib, dexamethasone, dosage, efficacy

          Comments

          Comment on this article